ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

ClinicalTrials.gov ID: NCT02782741

Public ClinicalTrials.gov record NCT02782741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease

Study identification

NCT ID
NCT02782741
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
101 participants

Conditions and interventions

Interventions

  • Alglucosidase alfa (GZ419829) Drug
  • Avalglucosidase alfa (GZ402666) Drug

Drug

Eligibility (public fields only)

Age range
3 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 1, 2016
Primary completion
Mar 18, 2020
Completion
May 30, 2023
Last update posted
Apr 3, 2024

2016 – 2023

United States locations

U.S. sites
21
U.S. states
18
U.S. cities
21
Facility City State ZIP Site status
Investigational Site Number 8400015 Phoenix Arizona 85013
Investigational Site Number 8400020 Los Angeles California 90095
Investigational Site Number 8400011 Orange California 92868
Investigational Site Number 8400017 Stanford California 94305
Investigational Site Number 8400016 Gainesville Florida 32610
Investigational Site Number 8400007 Decatur Georgia 30033
Investigational Site Number 8400023 Chicago Illinois 60611
Investigational Site Number 8400002 Iowa City Iowa 52242
Investigational Site Number 8400012 Kansas City Kansas 66160-7321
Investigational Site Number 8400010 Boston Massachusetts 02114
Investigational Site Number 8400001 Detroit Michigan 48201
Investigational Site Number 8400019 Minneapolis Minnesota 55455
Investigational Site Number 8400026 Great Neck New York 11020
Investigational Site Number 8400008 Valhalla New York 10595
Investigational Site Number 8400006 Durham North Carolina 27710
Investigational Site Number 8400009 Cincinnati Ohio 45267-0542
Investigational Site Number 8400014 Portland Oregon 97239
Investigational Site Number 8400025 Pittsburgh Pennsylvania 15213
Investigational Site Number 8400018 Salt Lake City Utah 84132
Investigational Site Number 8400005 Fairfax Virginia 22030
Investigational Site Number 8400024 Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02782741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02782741 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →